February 24, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Notice regarding the transition to a company withan audit and supervisory committee and nomination of directors
SymBio Pharmaceuticals Limited (“the Company”) today announced that, pursuant to a resolution
passed by the Company’s Board of Directors today, the Company will transition from a company with aboard of company auditors to a company with an audit and supervisory committee. This transition aims
to further strengthen corporate governance which increases the audit functionality of the Board ofDirectors. The transition will proceed provided that it is approved at the 17th Annual General Meetingof Shareholders scheduled for March 29, 2022.
In addition, pursuant to a resolution passed by the Company’s Board of Directors today, proposals forthe election of five (5) directors (excluding directors who are Audit and Supervisory Committee
members), three (3) director candidates who will be the Audit and Supervisory Committee members,and one (1) substitute member for the Audit and Supervisory Committee will be submitted to the 17thAnnual General Meeting of Shareholders scheduled for March 29, 2022, as set forth below.
The partial amendment of the Articles of Incorporation in connection with this transition will beseparately disclosed in the "Notice of Partial Amendment to the Articles of Incorporation" dated today.
1. Transition towards a company with an audit and supervisory committee(1) Purpose of transition
・ The Audit and Supervisory Committee members who are responsible for auditing the performanceof directors. This system will further enhance corporate governance by strengthening thesupervisory function of the Board of Directors and reinforcing the monitoring system.
・ By allowing the Board of Directors to delegate a wide range of business decisions to directors, theCompany will separate the business operation and supervision, expedite management decisionmaking, and enhance corporate value.
(2) Transition period
If the amended Articles of Incorporation are approved as drafted at the 17th Annual General Meetingof Shareholders scheduled for March 24, 2022, we will transition to a company with an audit andsupervisory committee as of the same date.

12. Director nomination after the transition to a company with an audit and supervisory committee(1) Nomination of candidates for the Board of Directors (excluding directors who are Audit andSupervisory Committee members)(i) Re-nominations
Mr. Fuminori Yoshida, Representative Director, President and CEO
Mr. Shigetoshi Matsumoto, Representative Director (outside director)
Dr. Bruce David Cheson, Representative Director (outside director)
Mr. Eiji Ebinuma, Representative Director (outside director)*Mr. Shigetoshi Matsumoto, Dr. Bruce David Cheson, Mr. Eiji Ebinuma are candidates for outsidedirectors as defined in Article 2, Item 15 of the Companies Act.
(ii) Newly nominated
Mr. Hirotama Ito, current Executive Vice President, Corporate Officer and COO
Profile of the candidate

April 1994
January 2002
April 2005
October 2006
March 2008
October 2012
October 2014

Research Scientist, Discovery Research Institute, Chugai
Pharmaceutical Co., Ltd.
Researcher, Research Center for Advanced Science andTechnology, University of Tokyo
Researcher, Forerunner Pharma Research Co., Ltd.
Molecular Imaging Marketing Leader, GE Yokogawa MedicalSystems, Inc.
Head of Marketing Planning Department, GE Healthcare
Japan Corporation
Director of Strategic Marketing, GE Healthcare Asia Pacific

October 2017

Special Lecturer, Graduate School of Medical Engineering,
Kyoto University
Head of Headquarters Sales, GE Healthcare JapanCorporationVisiting Associate Professor, Graduate School of Management,
GLOBIS University
President and Representative Director, Tecan Japan Co., Ltd.

June 2018

Outside Director, Adways Inc. (current)

April 2021

Professor, Graduate School of Management, GLOBIS
University (current)
Executive Vice President, Corporate Officer and COO of theCompany (current)

January 2016
April 2017

February 2022

(2) Nomination of candidates for the Audit and Supervisory Committee
Newly nominated
Mr. Kiyoshi Watanabe, current full-time Corporate Auditor
Mr. Kesao endo, current Corporate Auditor
Mr. Yasuhiro Tamou, current Corporate Auditor*The above candidates are candidates for outside directors as defined in Article 2, Item 15 of the2Companies Act.
(3) Nomination of Candidate as a substitute member of the Audit & Supervisory Committee
Newly nominatedMr. Takashi Watanabe, current substitute member of the Audit & Supervisory Board (Outside)*The above candidate is a substitute candidate for outside director as defined in Article 2, Item 15of the Companies Act.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

3